Obsidian Therapeutics Files Prospectus Related To Resale Of Up To 29,164,045 Shares Of Common Stock By Selling Stockholders
-SEC Filing
Stocks · News reference
Piper Sandler Initiates Coverage On Obsidian Therapeutics with Overweight Rating, Announces Price Target of $42
Piper Sandler analyst Kelsey Goodwin initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Overweight rating and announces Price Target of $42.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday
US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.
This Civeo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Analysts change outlook on top Wall Street names, including initiations, upgrades, and downgrades. Check our analyst ratings page for details.
Obsidian Therapeutics Enrolls First Participant In Its Phase 1/2 Agni-01 Trial Of Amsokigene Autoleucel To Treat Advanced Or Metastatic Melanoma
Obsidian Therapeutics, Inc. ("Obsidian") (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell